Biolife Solutions (BLFS) Cash & Equivalents (2010 - 2026)

Biolife Solutions (BLFS) has 17 years of Cash & Equivalents data on file, last reported at $22.8 million in Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $22.8 million, down 65.91% year-over-year; the trailing twelve-month figure through Mar 2026 was $22.8 million (down 65.91% YoY), and the FY2025 annual result was $33.0 million, down 63.91% from the prior year.
• Cash & Equivalents fell to $22.8 million in Q1 2026 per BLFS's latest filing, from $33.0 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $91.5 million in Q4 2024 and troughed at $19.1 million in Q1 2023.
• A 5-year average of $33.5 million and a median of $27.0 million in 2022 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2022 and 2024: Cash & Equivalents tumbled 72.17% in 2022, then jumped 228.14% in 2024.
• A 5-year view of Cash & Equivalents shows it stood at $19.4 million in 2022, then soared by 43.48% to $27.9 million in 2023, then jumped by 228.14% to $91.5 million in 2024, then slumped by 63.91% to $33.0 million in 2025, then tumbled by 30.92% to $22.8 million in 2026.
• Business Quant data shows BLFS's Cash & Equivalents at $22.8 million in Q1 2026, $33.0 million in Q4 2025, and $29.5 million in Q3 2025.